Latin America Vascular Stent Market Research Report – Segmented By Product (Peripheral Stents, Coronary Stents, EVAR Stent Grafts), Type, Mode of Delivery, Material, End-user, Country (Mexico, Brazil, Argentina, Chile and Rest of Latin America) - Industry Analysis From 2026 to 2034
In 2024, the Latin America Vascular Stent Market was valued at USD 1.86 billion and is forecasted to grow to USD 4.95 billion by 2033, at a CAGR of 11.5%.
Vascular Stent is a medical device used in the treatment of vascular diseases, particularly those affecting the coronary and peripheral arteries. Vascular stents—small, expandable tubes typically made from metal or polymer—are deployed during angioplasty procedures to restore and maintain blood flow in narrowed or blocked arteries. Their application is critical in managing cardiovascular conditions such as coronary artery disease (CAD), peripheral artery disease (PAD), and other vascular complications.
In Latin America, the demand for vascular stents has been shaped by the rising prevalence of chronic diseases, an aging population, and growing access to interventional cardiology services. Brazil and Mexico lead the regional market due to their relatively advanced healthcare infrastructures and higher patient volumes undergoing cardiovascular interventions. According to the Pan American Health Organization (PAHO), cardiovascular diseases account for nearly 30% of all deaths in the region, underlining the severity of the health burden and the need for effective treatment solutions such as vascular stents. Additionally, as per the World Bank, over 65% of Latin Americans now have access to hospital-based cardiovascular care, although disparities persist in rural and low-income areas.
Technological advancements have also influenced the market, with increasing adoption of drug-eluting stents (DES) over bare-metal stents (BMS) due to their superior long-term outcomes. Despite progress, affordability, regulatory complexity, and uneven healthcare access remain critical issues shaping the market’s trajectory.
The increasing prevalence of cardiovascular diseases (CVDs), particularly coronary artery disease (CAD) and peripheral artery disease (PAD), is one of the most significant drivers of the Latin America Vascular Stent Market. The rise in sedentary lifestyles, unhealthy dietary habits, and obesity has exacerbated the burden of these diseases, especially in urban populations. According to the Pan American Health Organization (PAHO), more than 30% of adults in the region suffer from hypertension, a major risk factor for CAD and a key contributor to the need for vascular interventions such as stenting. In tandem with disease prevalence, the number of percutaneous coronary interventions (PCIs) performed across the region has grown steadily.
The gradual expansion of healthcare infrastructure and improved access to medical insurance are other key drivers of the Latin America Vascular Stent Market. Over the past decade, several countries in the region have made significant strides in strengthening their healthcare systems. For instance, Brazil’s Unified Health System (SUS) provides free access to cardiovascular treatments for over 70% of the population, as reported by the Brazilian Ministry of Health. In Mexico, the expansion of the public health insurance scheme—Seguro Popular—before its transformation into the Instituto de Salud para Bienestar (INSABI)—helped increase access to advanced cardiac care for millions of previously uninsured citizens.
Additionally, private healthcare spending is on the rise, particularly in countries like Chile and Colombia, where private insurance penetration exceeds 25%, as noted by the OECD. The combination of improved infrastructure and expanded coverage has significantly enhanced the affordability and availability of vascular stents, positioning the market for sustained growth.
The high cost associated with advanced stent technologies, particularly drug-eluting stents (DES) and bioresorbable vascular scaffolds (BVS), is a major restraint in the Latin America Vascular Stent Market. While DES has demonstrated superior clinical outcomes compared to bare-metal stents (BMS), its significantly higher price remains a barrier to widespread adoption, especially in public healthcare systems. In contrast, the public healthcare budget in many Latin American countries does not fully cover the cost of these advanced devices, limiting patient access.
The World Bank estimates that nearly 30% of Latin Americans live below the national poverty line, making out-of-pocket payments for high-cost medical devices unfeasible. In countries like Peru and Bolivia, where public health coverage is limited, over 60% of healthcare expenditures are paid directly by patients, as per the Pan American Health Organization (PAHO). This financial burden restricts the use of advanced vascular stents to a small proportion of the population, primarily in private healthcare settings. Furthermore, procurement delays and budget constraints in government hospitals often result in the continued reliance on older, less effective stent types.
The Latin America Vascular Stent Market also faces challenges due to the complex and often lengthy regulatory approval processes for medical devices. Unlike in more developed markets such as the United States or Europe, where regulatory pathways are standardized and well-established, Latin American countries have varying regulatory frameworks that can delay market entry for new vascular stent technologies. Like, countries like Brazil, Argentina, and Mexico require separate and often redundant approval procedures, which can extend the time to market by 12–18 months.
The Brazilian health regulatory agency, ANVISA, in particular, is known for its rigorous and time-consuming evaluation process. As per a 2022 report by the Brazilian Medical Device Association (ABIMED), the average time for approval of cardiovascular devices in Brazil is approximately 24 months, compared to 6–8 months in the European Union. This delay discourages international manufacturers from entering or expanding in the Latin American market, limiting the availability of innovative stent technologies. Additionally, regulatory uncertainty in countries like Venezuela and Ecuador has further hampered investment and product launches. These inefficiencies not only affect the pace of technological adoption but also reduce competition, leading to higher device prices and reduced patient access.
The expanding adoption of telemedicine and remote patient monitoring (RPM) technologies is a promising opportunity for the Latin America Vascular Stent Market. As the region grapples with uneven healthcare access, especially in rural and underserved areas, digital health solutions are playing a pivotal role in improving post-operative care and long-term monitoring of patients with implanted vascular stents.
The integration of RPM systems with cardiovascular care enables physicians to monitor stent performance, detect complications early, and manage risk factors such as hypertension and diabetes more effectively. The Brazilian Ministry of Health pointed out in 2023 that telehealth initiatives had increased patient follow-up rates by nearly 40% in remote regions, leading to better outcomes post-stent implantation. Additionally, digital platforms are facilitating data collection and analysis, which supports the development of personalized treatment plans and improves procedural success rates.
The growing number of public-private partnerships (PPPs) aimed at strengthening cardiovascular healthcare delivery is another significant opportunity for the Latin America Vascular Stent Market. Governments across the region are increasingly collaborating with private healthcare providers, international organizations, and medical device manufacturers to expand access to advanced treatments such as vascular stenting.
In Mexico, for example, the Ministry of Health partnered with private hospitals and device companies to establish regional cardiovascular centers equipped with catheterization labs, significantly increasing the number of PCI procedures performed annually. Similarly, in Colombia, the government collaborated with the Pan American Health Organization (PAHO) and private firms to procure stents at reduced costs through centralized bidding, improving affordability and availability. These partnerships not only enhance procedural capacity but also encourage technology transfer and local manufacturing, reducing dependency on imports and lowering device costs.
The inconsistency in reimbursement policies across the region is one of the major challenges facing the Latin America Vascular Stent Market. Unlike in more developed markets where standardized reimbursement frameworks exist, Latin American countries have fragmented and often unpredictable reimbursement systems, particularly for high-cost medical devices such as drug-eluting stents (DES). According to the Latin American Society of Interventional Cardiology (SOLACI), reimbursement coverage for DES varies widely—from full coverage in select private insurance plans in Chile and Brazil to limited or no coverage in public health systems in countries like Peru and Ecuador.
As per the Pan American Health Organization (PAHO), in many cases, reimbursement decisions are made at the institutional or regional level rather than nationally, leading to disparities in patient access. In Brazil, for instance, while the Unified Health System (SUS) covers stent procedures, it often prioritizes bare-metal stents due to budget constraints, despite the clinical superiority of DES. This lack of uniformity discourages device manufacturers from investing in market expansion and limits the adoption of advanced stent technologies, ultimately affecting patient outcomes and market growth.
The shortage of skilled interventional cardiologists and inadequate catheterization laboratory (cath lab) infrastructure, particularly in rural and lower-income areas, is another pressing challenge in the Latin America Vascular Stent Market. According to the Latin American Society of Interventional Cardiology (SOLACI), there is a significant disparity in the number of interventional cardiologists per capita across the region. Brazil, for example, has approximately 2.5 interventional cardiologists per million people, while countries like Bolivia and Paraguay have less than 0.5 per million.
In countries like Honduras and Guatemala, the lack of cath labs in public hospitals forces patients to seek treatment in the private sector or abroad, significantly increasing the financial burden. Additionally, the training and certification process for interventional cardiologists remains lengthy and uneven across countries, further exacerbating the human resource gap.
The coronary stents segment accounted for the largest share of the Latin America Vascular Stent Market with 5.3% of total volume in 2024. High prevalence of coronary artery disease (CAD) and the increasing number of percutaneous coronary interventions (PCIs) performed across the region is driving the growth of the coronary stents segment. According to the Latin American Society of Interventional Cardiology (SOLACI), over 500,000 PCIs were conducted in Latin America in 2022, with Brazil alone accounting for nearly 40% of the procedures. The growing adoption of drug-eluting stents (DES) in PCI procedures has further reinforced the market leadership of coronary stents. Additionally, the expansion of public and private healthcare coverage for cardiovascular procedures has increased patient access to stent implantation.
The EVAR (Endovascular Aneurysm Repair) stent grafts segment is the fastest-growing segment in the Latin America Vascular Stent Market and is projected to expand at a CAGR of 11.4%. The rising incidence of abdominal aortic aneurysms (AAAs) and the increasing preference for minimally invasive treatment options are propelling the growth of the EVAR (Endovascular Aneurysm Repair) stent grafts segment. According to the Global Burden of Disease Study 2021, the number of AAA cases in Latin America has risen over the past decade, particularly among the aging population. The adoption of EVAR procedures has been further accelerated by technological advancements and the expansion of catheterization lab infrastructure in major hospitals. Moreover, public health initiatives in Argentina and Chile have facilitated better access to vascular surgical care, supporting the uptake of EVAR stent grafts.
The Drug-Eluting Stents (DES) segment held the biggest share of the Latin America Vascular Stent Market of 63.5% of total stent sales in 2024. Their superior clinical outcomes compared to bare-metal stents (BMS), particularly in reducing restenosis rates and improving long-term patient survival are among the main reasons behind the growth of the DES segment. Additionally, growing awareness among cardiologists and patients regarding the benefits of DES has led to increased adoption across both private and public healthcare systems. As per the Brazilian Ministry of Health, DES utilization in the Unified Health System (SUS) increased by 30% between 2019 and 2023, despite budget constraints. Furthermore, the entry of cost-effective DES variants from domestic and international manufacturers has made these devices more accessible.
The bioabsorbable stents segment represents the fastest-growing segment in the Latin America Vascular Stent Market, with a projected CAGR of 14.2% in the future. Unlike traditional metal stents, bioabsorbable stents dissolve over time after supporting the artery, reducing the risk of long-term complications such as stent thrombosis and vessel rigidity. The expansion of this segment is also being driven by increased investment from major medical device manufacturers in clinical research and product development. Companies such as Abbott and Biotronik have launched pilot programs in Latin America to evaluate the efficacy of bioabsorbable stents in local patient populations.
The balloon-expanding stents segment constituted the prominent category in the Latin America Vascular Stent Market by capturing 65.4% of the total volume in 2024. Their widespread use in coronary interventions, where precise deployment and high radial strength are critical is driving the lead position of balloon-expanding stents segment. The preference for balloon-expanding stents is further reinforced by their compatibility with a wide range of lesion types and their proven track record in clinical settings. Additionally, the availability of cost-effective stent variants from both global and regional manufacturers has supported their widespread adoption.
The Self-expanding stents segment is emerging as the fastest-growing in the Latin America Vascular Stent Market and is projected to grow at a CAGR of 12.6% from 2025 to 2033. These stents are increasingly used in peripheral vascular interventions, particularly in the treatment of iliac and femoral artery diseases. Technological advancements in stent design and material composition have also contributed to the rising adoption of self-expanding stents. Additionally, increasing investment in vascular cath labs and training programs for interventionalists has improved procedural access across the region.
Brazil led the Latin America Vascular Stent Market by accounting for 31.2% of total revenue in 2024. As the region’s largest economy and healthcare market, Brazil benefits from a well-established network of interventional cardiology centers and a high volume of percutaneous coronary interventions (PCIs). The Unified Health System (SUS) provides free access to cardiovascular care for over 70% of the population, although budget constraints often limit the availability of advanced stent types. The market is further supported by increasing private healthcare expenditure, growing awareness of cardiovascular diseases, and rising adoption of minimally invasive procedures. Additionally, the expansion of catheterization labs and the presence of leading medical device manufacturers have strengthened Brazil’s position as the dominant market in Latin America.
Argentina is positioning itself as the second-largest contributor in the region. The country has a relatively advanced healthcare system, particularly in Buenos Aires and other major cities, where interventional cardiology services are well developed. The government has made efforts to improve access to cardiovascular care through public health initiatives, including the inclusion of stent procedures under national insurance schemes. Additionally, the presence of several private hospitals and diagnostic centers has increased procedural capacity. Despite economic volatility and currency fluctuations, Argentina remains a key market for vascular stents due to its strong medical infrastructure and growing patient demand.
Chile holds a significant portion of the Latin America Vascular Stent Market which is driven by a well-organized healthcare system and high levels of medical device adoption. The country has one of the most developed healthcare infrastructures in the region, with a high penetration of private health insurance. The use of drug-eluting stents (DES) is particularly high in Chile. Additionally, the country has invested in expanding catheterization lab capacity. As per the Pan American Health Organization (PAHO), Chile’s structured approach to cardiovascular disease prevention and management has contributed to increased procedural volumes and improved patient outcomes, reinforcing its position as a key market in the region.
Mexico represents a notable share of the Latin America Vascular Stent Market and is driven by a combination of rising cardiovascular disease prevalence and expanding healthcare infrastructure. The country has a dual healthcare system comprising public institutions and private providers, both of which contribute to the growing adoption of vascular stents. The government has implemented various initiatives to improve access to cardiovascular care, including the expansion of the Instituto de Salud para Bienestar (INSABI), which provides coverage for stent procedures in public hospitals. Additionally, the presence of international medical device manufacturers and growing private healthcare investment have enhanced product availability.
The Rest of Latin America accounts for a considerable portion of the regional vascular stent market, with Colombia, Peru, and Ecuador emerging as key contributors. These countries are experiencing steady growth in cardiovascular interventions due to improving healthcare infrastructure and increasing government support for cardiac care. Additionally, Ecuador has made strides in cardiovascular disease management, with increased public funding for interventional cardiology programs.
Noteworthy companies dominating the Latin American Vascular Stent Market profiled in this report are Medtronic, plc (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), BIOTRONIK SE & Co. KG (Germany), B. Braun Melsungen AG (Germany), Terumo Corporation (Japan), STENTYS SA (France), MicroPort Scientific Corporation (China), Meril Life Sciences Pvt. Ltd. (India), Vascular Concepts (India), W. L. Gore and Associates (U.S.), C. R. Bard (U.S.), Endologix, Inc. (U.S.), Lombard Medical Technologies (U.K.), Translumina GmbH (Germany), and JOTEC GmbH (Germany).
The Latin America Vascular Stent Market is characterized by a mix of established global players and emerging regional manufacturers, creating a competitive yet evolving landscape. While multinational companies dominate due to their advanced product portfolios and strong brand recognition, local firms are increasingly gaining traction by offering cost-effective alternatives. The market is highly fragmented, with competition centered around technological innovation, pricing strategies, and localized distribution capabilities. Companies are focusing on enhancing their clinical support systems, expanding their regional presence, and adapting to the diverse regulatory environments across Latin American countries. The growing demand for high-quality vascular interventions, coupled with increasing healthcare expenditure, has intensified the race for market share. Additionally, partnerships with public healthcare systems and investments in physician training programs are becoming key differentiators. As the region continues to develop its cardiovascular care infrastructure, the competition is expected to further intensify, with companies striving to balance affordability, innovation, and accessibility to maintain a sustainable foothold in the market.
Abbott Laboratories is a global leader in the vascular stent market and holds a strong presence in Latin America. The company is widely recognized for its pioneering work in drug-eluting stents, particularly with the development of the Absorb bioresorbable vascular scaffold. Abbott has strategically expanded its footprint in the region through partnerships, localized manufacturing, and collaborations with regional healthcare providers. Its commitment to innovation and patient-centric solutions has enabled it to maintain a competitive edge in both coronary and peripheral stent segments.
Medtronic is another dominant player with a robust portfolio of vascular stents, including coronary, peripheral, and aortic stent grafts. In Latin America, Medtronic has focused on strengthening its distribution network and enhancing clinical education for healthcare professionals. The company’s emphasis on research and development, combined with its strategic presence in major markets like Brazil and Mexico, has positioned it as a key supplier of advanced stent technologies. Medtronic also collaborates with public health systems to improve access to high-quality vascular care.
Biotronik is a leading European-based cardiovascular device manufacturer with a growing influence in the Latin America Vascular Stent Market. The company is known for its innovative stent technologies, including biodegradable polymer-coated and drug-eluting stents. Biotronik has invested heavily in clinical trials and physician training programs in the region, fostering strong relationships with interventional cardiologists. Its commitment to delivering high-performance, durable, and safe vascular solutions has helped it gain a loyal customer base across Latin America.
One of the primary strategies employed by key players in the Latin America Vascular Stent Market is expanding regional distribution networks. Companies are strengthening their supply chains and collaborating with local distributors to ensure consistent product availability across both urban and rural healthcare facilities. This approach enhances accessibility and supports the timely delivery of stents, especially in public hospitals with high procedural volumes.
Another critical strategy is investing in clinical education and physician training. Market leaders are actively conducting workshops, certification programs, and live demonstrations to familiarize interventional cardiologists with the latest stent technologies. By building clinical confidence and trust, manufacturers can drive adoption and preference for their products in key procedures such as PCI and peripheral interventions.
Lastly, companies are engaging in strategic partnerships and collaborations with local governments, academic institutions, and healthcare providers. These alliances help in navigating regulatory landscapes, improving reimbursement frameworks, and aligning product development with regional healthcare needs, thereby solidifying long-term market presence and competitiveness.
This research report on the Latin American Vascular Stent Market has been segmented and sub-segmented into the following categories.
By Product
By Type
By Mode of Delivery
By Material
By End User
By Country
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 1600
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region